Search Results for “GSK ” – Page 17 – media

GlaxoSmithKline will Shut Bangladesh Drug Manufacturing Operations by End 2018

GlaxoSmithKline will be closing its drug manufacturing operations in Bangladesh by the end of this year and will remain only with its healthcare business that produces Sensodyne, Horlicks and Glaxose-D.
- Source: Reuters
- 637
- July 31, 2018
Company Insight GSK Pharma Asia
GlaxoSmithKline Invests $300 Million in 23andMe

23andMe declared an investment of $300 million on Wednesday, made by GlaxoSmithKline to attain special access to their DNA database.
- Source: HealthcareIT News
- 585
- July 27, 2018
Company Insight genetic testing GSK
Enquiry for Nucala in COPD

Nucala (mepolizumab) was first approved as the first anti-IL5 treatment for adults and adolescents with severe asthma accompanied by eosinophilic phenotype in the United States during November 2015. Later it was approved to treat eosinophilic granulomatosis with polyangiitis (EGPA).
- Source: BioPharmaDive
- 773
- July 26, 2018
COPD GSK New Approvals
Senators Write to GlaxoSmithKline to Boost Shingrix Supply

As a result of the high demand for GlaxoSmithKline's new shingles vaccine, Shingrix, two U.S. senators have urged the pharma giant to boost inventory levels on facing a shortage in the supplies even after the company established their "fair and equitable" process to ship Shingrix doses.
- Source: FiercePharma
- 818
- July 10, 2018
Company Insight GlaxoSmithKline shingles Shingrix vaccine
Shingrix Orders Limited by GlaxoSmithKline

Order limits have been introduced by GSK owing to high demand for the product, as per a note on the CDC’s website. In the meantime, shipping delays are being experienced by providers and according to the CDC, the delays are likely to remain throughout the year.
- Source: FiercePharma
- 674
- June 22, 2018
GSK Market Views shingles
Adaptimmune Lends Credence to T-Cell Therapy

Updated clinical data on its T-cell therapies has been presented by Adaptimmune. The GlaxoSmithKline-partnered NY-ESO SPEAR T-cells have been linked by the latest readouts to a 50% partial response rate in heavily pretreated cancer patients and have led to the positioning of Adaptimmune for dialing up of dosing of two wholly owned assets.
- Source: FierceBiotech
- 576
- June 5, 2018
Company Insight GSK T-cell therapies
Boosted by China launch, Merck’s Gardasil turns in a big first-quarter performance

Merck generated more than $1.5 billion in first-quarter vaccine sales. (Merck)
- Source: fiercepharma
- 584
- May 9, 2018
Gardasil HPV vaccine Merck
Shingrix approved in Europe and Japan for the prevention of shingles in adults aged 50 and over

The only shingles vaccine to achieve ≥90% efficacy across all age groups studied
- Source: gsk
- 617
- May 7, 2018
EC GSK post-herpetic neuralgia Shingrix
China hands out landmark nod with lightning speed

GSK’s Cervarix and Merck’s previous version of Gardasil took about 10 years to reach the Chinese market. (Merck)
- Source: fiercepharma
- 915
- May 2, 2018
CFDA Gardasil GSK New Approvals
Specialty Vaccines for Overlooked Infectious Diseases–Challenges and Opportunities

Developing specialty vaccines for emerging and overlooked infectious diseases is a challenging and rewarding enterprise with specific opportunities and problems. Large companies have not historically prioritized this area and instead have focused on the development and commercialization of routine vaccines and vaccines for diseases with more significant global markets.
- Source: fiercepharma
- 480
- April 28, 2018
Researches vaccines

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.